On the other hand, large‐scale clinical trials have demonstrated that cell cycle inhibitors, such as the FDA‐approved abemaciclib and ribociclib, which are CDK4/6 inhibitors, significantly extended progression‐free survival of breast cancer patients (Hortobagyi et al. 2016; Sledge et al. 2017). This evidence concerns the gene CDK4 and breast carcinoma.